Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Korea.
Laboratory of Veterinary Internal Medicine, Research Institute of Veterinary Science, College of Veterinary Medicine, Jeju National University, Jeju, 63243, Korea.
BMC Vet Res. 2024 Aug 22;20(1):375. doi: 10.1186/s12917-024-04216-3.
The aim of this study was to evaluate the adverse effects of allogeneic mesenchymal stem cells (MSCs) transplanted via intravenous infusion in dogs and examine their safety. We performed a retrospective analysis of various clinical assessments, including physical examination, blood tests, and radiographs, and monitored the formation of neoplasms during a 6-month follow-up period in 40 client-owned dogs that received intravenous infusion of adipose tissue-derived MSCs (AT-MSCs) for the treatment of various underlying diseases between 2012 and 2018.
No significant adverse effects of MSC therapy were detected by clinical assessment, blood tests, or radiographic examination in the 6-month follow-up period after the first MSC treatment. Additionally no new neoplasms were observed during this period.
To our knowledge, this study is the first to evaluate the safety aspects (≥ 6 months) associated with intravenous allogeneic AT-MSC infusion. These results suggest that allogenic AT-MSC infusion could be a useful and relatively safe therapeutic approach in canines.
本研究旨在评估经静脉输注异体间充质干细胞（MSCs）对犬的不良反应，并评估其安全性。我们对 40 只接受脂肪组织来源的间充质干细胞（AT-MSCs）静脉输注以治疗各种基础疾病的患犬进行了回顾性分析，这些患犬于 2012 年至 2018 年期间接受了治疗。我们进行了各种临床评估，包括体格检查、血液检查和影像学检查，并在第一次 MSC 治疗后 6 个月的随访期间监测肿瘤的形成。
在首次 MSC 治疗后 6 个月的随访期间，通过临床评估、血液检查或影像学检查均未发现 MSC 治疗有明显的不良反应。此外，在此期间未观察到新的肿瘤。
据我们所知，这是第一项评估静脉内同种异体 AT-MSC 输注相关安全性（≥6 个月）的研究。这些结果表明，同种异体 AT-MSC 输注可能是犬科动物一种有用且相对安全的治疗方法。
